N6-ciklopentiladenozin

N⁶-ciklopentil adenozin
Nazivi
	IUPAC naziv (2R,3R,4S,5R)-2-[6-(ciklopentilamino)purin-9-il]-5-(hidroksimetil)oksolan-3,4-diol
Identifikacija
CAS broj	41552-82-3;
3D model (Jmol)	interaktivna slika;
PubChem C ID	657378;
	SMILES C1CCC(C1)NC2=NC=NC3=C2N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O; ; ; ; ; ;
Svojstva
Hemijska formula	C15H21N5O4
Molarna masa	335,36 g·mol−1
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	verifikuj (šta je ?)
	Reference infokutije

N⁶-ciklopentiladenozin (CPA) je lek koji deluje kao selektivni agonist adenozinskog A₁ receptora.^[3] On uglavnom ima kardiovaskularno dejstva sa samo suptilnim izmenama ponašanja.^[4] CPA je u širokoj upotrebi u naučnim istraživanjima adenozinskog receptora i korišten je za razvoj velike familije derivata.^[5]^[6]^[7]^[8]^[9]

Reference

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Williams M, Braunwalder A, Erickson TJ (1986). „Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue”. Naunyn-Schmiedeberg's Archives of Pharmacology. 332 (2): 179—83. PMID 3703020. doi:10.1007/BF00511410.
^ Coffin VL, Spealman RD (1987). „Behavioral and cardiovascular effects of analogs of adenosine in cynomolgus monkeys”. The Journal of Pharmacology and Experimental Therapeutics. 241 (1): 76—83. PMID 3572798.
^ Zablocki JA, Wu L, Shryock J, Belardinelli L (2004). „Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF)”. Current Topics in Medicinal Chemistry. 4 (8): 839—54. PMID 15078215. doi:10.2174/1568026043450998.
^ Hutchinson SA, Scammells PJ (2004). „A(1) adenosine receptor agonists: medicinal chemistry and therapeutic potential”. Current Pharmaceutical Design. 10 (17): 2021—39. PMID 15279543. doi:10.2174/1381612043384204.
^ Elzein E, Kalla R, Li X, Perry T, Marquart T, Micklatcher M, Li Y, Wu Y, Zeng D, Zablocki J (2007). „N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists”. Bioorganic & Medicinal Chemistry Letters. 17 (1): 161—6. PMID 17045477. doi:10.1016/j.bmcl.2006.09.065.
^ Elzein E, Zablocki J (2008). „A1 adenosine receptor agonists and their potential therapeutic applications”. Expert Opinion on Investigational Drugs. 17 (12): 1901—10. PMID 19012505. doi:10.1517/13543780802497284.
^ Franchetti P, Cappellacci L, Vita P, Petrelli R, Lavecchia A, Kachler S, Klotz KN, Marabese I, Luongo L, Maione S, Grifantini M (2009). „N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice”. Journal of Medicinal Chemistry. 52 (8): 2393—406. PMID 19317449. doi:10.1021/jm801456g.

Vidi još

Spoljašnje veze

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[pmid3703020-3] Williams M, Braunwalder A, Erickson TJ (1986). „Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue”. Naunyn-Schmiedeberg's Archives of Pharmacology. 332 (2): 179—83. PMID 3703020. doi:10.1007/BF00511410.

[pmid3572798-4] Coffin VL, Spealman RD (1987). „Behavioral and cardiovascular effects of analogs of adenosine in cynomolgus monkeys”. The Journal of Pharmacology and Experimental Therapeutics. 241 (1): 76—83. PMID 3572798.

[pmid15078215-5] Zablocki JA, Wu L, Shryock J, Belardinelli L (2004). „Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF)”. Current Topics in Medicinal Chemistry. 4 (8): 839—54. PMID 15078215. doi:10.2174/1568026043450998.

[pmid15279543-6] Hutchinson SA, Scammells PJ (2004). „A(1) adenosine receptor agonists: medicinal chemistry and therapeutic potential”. Current Pharmaceutical Design. 10 (17): 2021—39. PMID 15279543. doi:10.2174/1381612043384204.

[pmid17045477-7] Elzein E, Kalla R, Li X, Perry T, Marquart T, Micklatcher M, Li Y, Wu Y, Zeng D, Zablocki J (2007). „N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists”. Bioorganic & Medicinal Chemistry Letters. 17 (1): 161—6. PMID 17045477. doi:10.1016/j.bmcl.2006.09.065.

[pmid19012505-8] Elzein E, Zablocki J (2008). „A1 adenosine receptor agonists and their potential therapeutic applications”. Expert Opinion on Investigational Drugs. 17 (12): 1901—10. PMID 19012505. doi:10.1517/13543780802497284.

[pmid19317449-9] Franchetti P, Cappellacci L, Vita P, Petrelli R, Lavecchia A, Kachler S, Klotz KN, Marabese I, Luongo L, Maione S, Grifantini M (2009). „N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice”. Journal of Medicinal Chemistry. 52 (8): 2393—406. PMID 19317449. doi:10.1021/jm801456g.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]